— The New York Times (@nytimes) August 18, 2015
The FDA on Tuesday approved flibanserin, a little pink pill designed to treat low libido in women, some 17 years after it approved Viagra, a little blue pill used to treat erectile disfunction in men. The drug, around which controversy has swirled, will be sold under the trade name Addyi and will be available by prescription as soon as October 17. Predictably, the drug’s supporters struck a celebratory tone while critics still derided the drug as a “mediocre” treatment for low sexual libido. It’s the first drug to treat low sexual libido in women to be approved by the FDA.
Read the full story at The Washington Post.